Join the conversation on Twitter – #HAH2018
Sponsored by the International Journal Human Antibodies
In association with the Integrative Medical Sciences Association
The 21st HUMAN ANTIBODIES & HYBRIDOMAS conference will be held at the Pullman Riga Old Town Hotel in Riga, the capital city of Latvia.
The HAH 2018 scientific programme will have a broadened scope from previous events with the addition of some new topic areas outlined in the scope section below.
As usual the scientific programme will include keynote lectures, contributed oral papers and poster presentations emphasising all key aspects of human antibody technologies, applications and engineering.
Scientific Advisory Panel
Programme Chairman: Professor Mark Glassy (UCSD Moores Cancer Center, San Diego, California, USA)
Mirek Gorny (New York University School of Medicine, New York, USA)
Henry Lowman (CytomX Therapeutics Inc., South San Francisco, California, USA)
Chris Scott (The Queen’s University, Belfast, Northern Ireland, UK)
Roberto Burioni (Universita Vita-Salute San Raffaele, Milan, Italy)
Jim Larrick (Panorama Research Inc., USA)
Alois Lang (GeNeuro SA, Geneva, Switzerland)
David P. Humphreys (UCB, Slough, UK)
Markus Enzelberger (MorphoSys AG, Martinsried, Germany)
Eszter Nagy (Arsanis GmbH, Vienna, Austria)
Sachdev Sidhu (University of Toronto, Canada)
Neil Brewis (F-star, Cambridge, UK)
Paul Kerr (Fusion Antibodies, Northern Ireland, UK)
Yan Wu (Kadmon Pharmaceuticals LLC, New York, USA)
Bob Kelley (Genentech Inc., South San Francisco, USA)
David Naor (The Hebrew University, Jerusalem, Israel)
Lynn MacDonald (Regeneron Pharmaceuticals, Tarrytown, New York, USA)
Jody Berry (Becton Dickinson, La Jolla, California, USA)
Maria Groves (Medimmune, Cambridge, UK)
Dale Ludwig (ImClone Inc., New York, USA)
Hermann Katinger and Dietmar Katinger (Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria)
Andrew T. Serafini (Kilpatrick Townsend, Seattle, Washington, USA)
Conference Scope
The scope of the HAH 2018 conference falls broadly the following main session categories:
- Infectious Diseases
- Autoimmunity
- Molecular Biology
- Emerging Technologies Clinical Applications
Therapeutic Antibodies - Cancer
- Anti-Infective Antibodies
- Intellectual Property & Legal Issues
For the 2018 and future meetings the scope is being expanded to include sessions on:
- Formulation
- Oral Delivery
- Combination Therapy
- Validity of Animal Models
- Peptide Drugs
- Immunotherapy of Cancer & Autoimmunity
